CL2019001623A1 - Uso de compuesto de carbamato para prevenir, aliviar o tratar temblores o el síndrome de temblor. - Google Patents

Uso de compuesto de carbamato para prevenir, aliviar o tratar temblores o el síndrome de temblor.

Info

Publication number
CL2019001623A1
CL2019001623A1 CL2019001623A CL2019001623A CL2019001623A1 CL 2019001623 A1 CL2019001623 A1 CL 2019001623A1 CL 2019001623 A CL2019001623 A CL 2019001623A CL 2019001623 A CL2019001623 A CL 2019001623A CL 2019001623 A1 CL2019001623 A1 CL 2019001623A1
Authority
CL
Chile
Prior art keywords
prevent
relieve
carbamate compound
tremor syndrome
treat
Prior art date
Application number
CL2019001623A
Other languages
English (en)
Spanish (es)
Inventor
Jin Uk Yoo
Hye Sung Lee
Han Ju Yi
Original Assignee
Sk Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sk Biopharmaceuticals Co Ltd filed Critical Sk Biopharmaceuticals Co Ltd
Publication of CL2019001623A1 publication Critical patent/CL2019001623A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CL2019001623A 2016-12-14 2019-06-12 Uso de compuesto de carbamato para prevenir, aliviar o tratar temblores o el síndrome de temblor. CL2019001623A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20160170225 2016-12-14

Publications (1)

Publication Number Publication Date
CL2019001623A1 true CL2019001623A1 (es) 2019-08-23

Family

ID=62558966

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019001623A CL2019001623A1 (es) 2016-12-14 2019-06-12 Uso de compuesto de carbamato para prevenir, aliviar o tratar temblores o el síndrome de temblor.

Country Status (14)

Country Link
US (1) US11033531B2 (enExample)
EP (1) EP3556364B1 (enExample)
JP (1) JP7086076B2 (enExample)
KR (1) KR102635941B1 (enExample)
CN (1) CN110267657B (enExample)
AU (1) AU2017374459B2 (enExample)
CA (1) CA3046300A1 (enExample)
CL (1) CL2019001623A1 (enExample)
ES (1) ES3039979T3 (enExample)
IL (1) IL267191B2 (enExample)
MX (1) MX391363B (enExample)
MY (1) MY198417A (enExample)
WO (1) WO2018111009A1 (enExample)
ZA (1) ZA201903749B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019098626A1 (ko) * 2017-11-14 2019-05-23 에스케이바이오팜 주식회사 후기 나트륨 전류의 증가와 관련된 질환을 예방 또는 치료하기 위한 카바메이트 화합물의 용도
JP7408643B2 (ja) * 2018-09-21 2024-01-05 エスケー バイオファーマスティカルズ カンパニー リミテッド カルバメート化合物及びそれを含む製剤の急性ストレス障害又は心的外傷後ストレス障害の予防、軽減又は治療のための使用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004527492A (ja) * 2001-02-27 2004-09-09 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 運動障害の予防もしくは治療における使用のためのカルバメート化合物
JP2007530694A (ja) 2004-03-29 2007-11-01 メルク　エンド　カムパニー　インコーポレーテッド ナトリウムチャネル遮断薬としてのビアリール置換ピラジノン
US7598279B2 (en) * 2005-04-22 2009-10-06 Sk Holdings Co., Ltd. Neurotherapeutic azole compounds
CN101657194B (zh) * 2007-03-05 2013-10-23 Indus生物技术私人有限公司 包含葫芦巴碱和4-羟基异亮氨酸的药物组合物及其方法
CN102803233B (zh) * 2009-06-22 2017-03-01 爱思开生物制药株式会社 制备氨基甲酸(r)‑1‑芳基‑2‑四唑基‑乙酯的方法
US8404461B2 (en) * 2009-10-15 2013-03-26 SK Biopharmaceutical Co. Ltd. Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester
ES2998534T3 (en) * 2013-03-12 2025-02-20 Bio Pharm Solutions Co Ltd Phenyl carbamate compounds for use in preventing or treating pediatric epilesy
KR102489052B1 (ko) * 2016-05-19 2023-01-16 에스케이바이오팜 주식회사 섬유근육통 또는 섬유근육통의 연관된 기능적 증후군을 예방 또는 치료하기 위한 카바메이트 화합물의 용도

Also Published As

Publication number Publication date
MX391363B (es) 2025-03-21
IL267191A (enExample) 2019-07-31
MX2019006941A (es) 2019-09-06
WO2018111009A1 (ko) 2018-06-21
JP7086076B2 (ja) 2022-06-17
ZA201903749B (en) 2022-01-26
CA3046300A1 (en) 2018-06-21
CN110267657A (zh) 2019-09-20
RU2019121914A3 (enExample) 2021-04-21
IL267191B2 (en) 2023-05-01
KR102635941B1 (ko) 2024-02-13
KR20190087573A (ko) 2019-07-24
EP3556364A4 (en) 2020-06-17
US20190336481A1 (en) 2019-11-07
JP2020502137A (ja) 2020-01-23
AU2017374459A1 (en) 2019-07-04
MY198417A (en) 2023-08-29
US11033531B2 (en) 2021-06-15
RU2019121914A (ru) 2021-01-15
CN110267657B (zh) 2022-12-13
EP3556364B1 (en) 2025-08-27
ES3039979T3 (en) 2025-10-28
IL267191B1 (en) 2023-01-01
EP3556364A1 (en) 2019-10-23
AU2017374459B2 (en) 2023-04-27
BR112019012000A2 (pt) 2019-10-29

Similar Documents

Publication Publication Date Title
DOP2019000117A (es) Nuevos derivados de quinolina
MX2022012313A (es) Oxisteroles y metodos de uso de los mismos.
CL2018002009A1 (es) Compuestos derivados de ciclopentanoperhidofenantreno, moduladores de fxr; composicion farmaceutica que comprende dichos compuestos; y su uso para el tratamiento de enfermedades colestásicas, fibróticas, hipercolesterolemia, entre otras.
UY37789A (es) Nuevos derivados de azaquinolina
MX2020011104A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
BR112017003658A2 (pt) composto, mistura, métodos para tratamento de uma doença e para inibição de uma glicosidase, e, composição farmacêutica.
BR112015022197A8 (pt) uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia
BR112016028845A2 (pt) composto, composição farmacêutica e uso de um composto
MX378509B (es) Compuesto de pirimidina y su uso farmaceutico.
MX2020004694A (es) Composiciones farmaceuticas inyectables de isoxazolina y su uso contra la infestacion de parasitos.
MX387658B (es) Métodos para tratar y/o prevenir queratosis actínica.
MX2019012522A (es) Compuestos y metodos terapeuticos.
PE20161385A1 (es) Formulacion inmunosupresora
CL2018003431A1 (es) Tratamiento de la enfermedad de parkinson.
MX2018014080A (es) Uso de compuesto de carbamato para prevenir o tratar fibromialgia o sindrome funcional asociado con fibromialgia.
MX377172B (es) Formulacion de combinacion de tesofensina y betabloqueante
AR094707A1 (es) Compuesto de quinazolin-4-amina, composición farmacéutica que lo comprende y su uso para el tratamiento de una enfermedad mediada por la quinasa rip2
SV2018005702A (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
BR112017022158A2 (pt) compostos, composições farmacêuticas e uso de um composto
CL2019001623A1 (es) Uso de compuesto de carbamato para prevenir, aliviar o tratar temblores o el síndrome de temblor.
CL2019001618A1 (es) Uso de compuestos de carbamato para prevención, alivio o tratamiento del trastorno bipolar.
BR112017024126B8 (pt) Composições farmacêuticas, composto a micronizado e/ou pelo menos um sal farmaceuticamente aceitável micronizado do composto a e uso dos mesmos
MX2018014081A (es) Uso de compuesto de carbamato para prevenir o tratar neuralgia trigeminal.
MX2021004342A (es) Uso de compuesto de carbamato para prevenir, aliviar o tratar neuropatía periférica diabética o neuropatía periférica inducida por quimioterapia.